Urine Test May Help Identify Autism Risk in Children

Why It Matters

By providing a biologically based, non‑behavioral marker, the test could shorten diagnostic delays, enabling earlier therapeutic interventions that improve long‑term outcomes and reduce the $3.6 million lifetime care cost per individual.

Key Takeaways

• Urine test detects autism with 90% sensitivity, 100% specificity
• Test measures 17 gut microbial metabolites linked to neurotransmitter pathways
• Study of 99 children across four US states shows consistent metabolite elevation
• Proposed ASD‑MDM subtype may encompass 90% of autism cases
• Early urine screening could accelerate interventions, reducing lifetime care costs

Pulse Analysis

Autism diagnosis in the United States still relies heavily on behavioral assessments, often leading to months or years of uncertainty for families. Recent advances in microbiome science have highlighted the gut‑brain axis as a potential source of objective biomarkers. The ASU team’s Microbially‑Derived Metabolite (MDM) System leverages this insight, quantifying a panel of 17 microbial by‑products that correlate with neurotransmitter precursors such as tyrosine, tryptophan, and phenylalanine. By translating complex metabolomic data into a single risk score, the test offers clinicians a rapid, non‑invasive triage tool that could shift the diagnostic paradigm toward earlier, biology‑driven identification.

The initial trial, spanning Arizona, Massachusetts, Tennessee, and Texas, demonstrated remarkable accuracy—90% sensitivity and perfect specificity—across a diverse pediatric cohort. Such performance suggests the test could flag high‑risk children well before traditional evaluations, allowing parents to pursue early interventions like speech therapy, behavioral programs, or emerging microbiota‑based treatments. Moreover, the identification of an ASD‑MDM phenotype, present in roughly nine‑tenths of cases, opens the door for personalized therapeutic strategies aimed at normalizing gut metabolite levels, potentially mitigating core symptoms linked to serotonin and dopamine dysregulation.

From a market and policy perspective, the test’s promise aligns with growing demand for precision diagnostics in neurodevelopmental disorders. If larger, multi‑ethnic studies confirm its utility, insurers may adopt coverage, reducing the economic burden of delayed treatment—currently estimated at $3.6 million per individual over a lifetime. Additionally, the commercial partnership with UK‑based Analutos hints at rapid international rollout, positioning the MDM System as a cornerstone of future autism care pathways while underscoring the need for rigorous validation and regulatory oversight.